WCN24-1001 EFFECT OF CORTICOSTEROIDS ON KIDNEY AND SAFETY OUTCOMES IN IGA NEPHROPATHY ACROSS DIFFERENT LEVELS OF PROTEINURIA AND EGFR: A POST HOC ANALYSIS OF THE TESTING STUDY

WCN24-1001 EFFECT OF CORTICOSTEROIDS ON KIDNEY AND SAFETY OUTCOMES IN IGA NEPHROPATHY ACROSS DIFFERENT LEVELS OF PROTEINURIA AND EGFR: A POST HOC ANALYSIS OF THE TESTING STUDY

Saved in:

Bibliographic Details
Main Authors:	Muh Geot Wong, Jicheng Lv, Brendon Neuen, Helen Monaghan, Laurent Billot, Vlado Perkovic, Hong Zhang, Dana Kim
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924003991
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Corticosteroid Effects in IgA Nephropathy by Baseline Proteinuria and Estimated GFR
by: Dana Kim, et al.
Published: (2025-06-01)

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy
by: Jingyi Li, et al.
Published: (2024-10-01)

Current status of clinical studies of IgA nephropathy with minimal proteinuria
by: SHI Yu-zhen, et al.
Published: (2020-01-01)

Corticosteroids in Patients With IgA Nephropathy: Is the Lower the Better?
by: Thomas Rauen, et al.
Published: (2024-07-01)

Serum Galactose-Deficient IgA1 Level Is Not Associated with Proteinuria in Children with IgA Nephropathy
by: M. Colleen Hastings, et al.
Published: (2012-01-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

Prognostic Value of Urinary Biomarkers in Proteinuria Progression in IgA Nephropathy Patients Treated with Budesonide
by: Christodoulos Keskinis, et al.
Published: (2025-04-01)

The proteinuria selectivity index value predicts the remission of IgA nephropathy: a retrospective cohort study
by: Ryunosuke Mitsuno, et al.
Published: (2024-12-01)

Clinicopathological features and renal dysfunction risk factors of IgA nephropathy patients presenting with mild proteinuria
by: LIU Jie, et al.
Published: (2018-01-01)

Correlation of E1 Lesions and CD68 Count with Proteinuria and Clinical Outcome in IgA Nephropathy
by: Sistla Radha, et al.
Published: (2022-04-01)

Exploring the mechanism of proteinuria reduction by hydroxychloroquine in IgA nephropathy using network pharmacology and molecular mocking
by: Meiqi Lu, et al.
Published: (2025-07-01)

Prognosis of IgA nephropathy patient with proteinuria remission by supportive therapy: cohort from screening failed Chinese patients in TESTING study
by: Yingman Guo, et al.
Published: (2024-12-01)

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY
by: Hernán Trimarchi, et al.
Published: (2024-04-01)

The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy
by: Dana Kim, et al.
Published: (2024-07-01)

Kidney Outcomes with Corticosteroid Treatment in IgA Nephropathy According to the Oxford-MEST-C Classification
by: Bancha Satirapoj, et al.
Published: (2025-03-01)

WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
by: Vlado Perkovic, et al.
Published: (2024-04-01)

Diabetic Nephropathy: Proteinuria, Inflammation, and Fibrosis
by: Shirong Zheng, et al.
Published: (2016-01-01)

IgA Nephropathy in the Elderly
by: Dana V. Rizk, et al.
Published: (2025-08-01)

Hydroxychloroquine sulfate for IgA nephropathy: mechanisms and therapeutic potential in improving proteinuria and alleviating disease progression - a literature review
by: Liao Yilei, et al.
Published: (2025-07-01)

Does corticosteroid treatment affect the progression of pediatric IgA nephropathy – a systematic review and meta-analysis
by: Bebby Shelby, et al.
Published: (2025-03-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy
by: Jincan Zan, et al.
Published: (2024-04-01)

Pulse Profile Variability of PSR J1022+1001 in NANOGrav Data
by: William Fiore, et al.
Published: (2025-01-01)

WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ATACICEPT VS PLACEBO ON PROTEINURIA AND RENAL FUNCTION PRESERVATION IN IGA NEPHROPATHY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

Is Childhood IgA Nephropathy Different From Adult IgA Nephropathy? A Narrative Review
by: Areefa Alladin-Karan, et al.
Published: (2025-03-01)

WCN25-932 STEROID (SYSTEMIC OR ENTERIC RELEASED BUDESONIDE) REFRACTORY NEPHROTIC RANGE PROTEINURIA IN IgA NEPHROPATHY; CAN TACROLIMUS BE AN ALTERNATIVE?- A CASE SERIES
by: RAJA SINGHAL, et al.
Published: (2025-02-01)

Application of hydroxychloroquine for IgA nephropathy
by: Xiao Yong-zhen, et al.
Published: (2021-01-01)

Unconventional T Cells in IgA Nephropathy
by: Zizhang Sheng, et al.
Published: (2025-02-01)

Corrigendum to “Is childhood IgA nephropathy different from adult IgA nephropathy? A narrative review”
Published: (2025-07-01)

WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

Clinical study on leflunomide combined with valsartan in the treatment of diabetic nephropathy proteinuria
by: WANG Li, et al.
Published: (2017-01-01)

Research advances of idiopathic membranous nephropathy with non-nephrotic range proteinuria
by: Sun Jing, et al.
Published: (2022-10-01)

WCN25-4378 OUTCOME OF USE OF ENTERIC RELEASED BUDESONIDE IN IgA NEPHROPATHY PATIENTS WITH NEPHROTIC AND SUBNEPHROTIC PROTEINURIA PRESENTATIONS: PROSPECTIVE COMPARATIVE STUDY IN TERTIARY CARE CENTRE
by: RAJA SINGHAL, et al.
Published: (2025-02-01)

The relationship between proteinuria and coronary risk: a systematic review and meta-analysis.
by: Vlado Perkovic, et al.
Published: (2008-10-01)

Dabigatran-Related Nephropathy in a Patient with Undiagnosed IgA Nephropathy
by: Rachele Escoli, et al.
Published: (2015-01-01)

Opportunities and challenges in the treatment of IgA nephropathy
by: Yang Yang, et al.
Published: (2025-07-01)

Characterisation of IgA Nephropathy in an Australian Cohort
by: Shriram Swaminathan, et al.
Published: (2025-01-01)

Serum Cytokine Profile in IgA Nephropathy
by: Friederike Selbach, MD, et al.
Published: (2025-02-01)